PMID- 17040570
OWN - NLM
STAT- MEDLINE
DCOM- 20061204
LR  - 20220318
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 6
DP  - 2006 Oct 13
TI  - Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 
      12p13, 17q12, and 20q13 amplifications in breast cancers.
PG  - 245
AB  - BACKGROUND: Oncogene amplification and overexpression occur in tumor cells. 
      Amplification status may provide diagnostic and prognostic information and may 
      lead to new treatment strategies. Chromosomal regions 8p12, 8q24, 11q13, 17q12 
      and 20q13 are recurrently amplified in breast cancers. METHODS: To assess the 
      frequencies and clinical impact of amplifications, we analyzed 547 invasive 
      breast tumors organized in a tissue microarray (TMA) by fluorescence in situ 
      hybridization (FISH) and calculated correlations with histoclinical features and 
      prognosis. BAC probes were designed for: (i) two 8p12 subregions centered on 
      RAB11FIP1 and FGFR1 loci, respectively; (ii) 11q13 region centered on CCND1; 
      (iii) 12p13 region spanning NOL1; and (iv) three 20q13 subregions centered on 
      MYBL2, ZNF217 and AURKA, respectively. Regions 8q24 and 17q12 were analyzed with 
      MYC and ERBB2 commercial probes, respectively. RESULTS: We observed amplification 
      of 8p12 (amplified at RAB11FIP1 and/or FGFR1) in 22.8%, 8q24 in 6.1%, 11q13 in 
      19.6%, 12p13 in 4.1%, 17q12 in 9.9%, 20q13Z (amplified at ZNF217 only) in 9.9%, 
      and 20q13Co (co-amplification of two or three 20q13 loci) in 8.5% of cases. The 
      8q24, 12p13, and 17q12 amplifications were correlated with high grade. The most 
      frequent single amplifications were 8p12 (9.8%), 8q24 (3.3%) and 12p13 (3.3%), 
      20q13Z and 20q13Co (1.6%) regions. The 17q12 and 11q13 regions were never found 
      amplified alone. The most frequent co-amplification was 8p12/11q13. 
      Amplifications of 8p12 and 17q12 were associated with poor outcome. Amplification 
      of 12p13 was associated with basal molecular subtype. CONCLUSION: Our results 
      establish the frequencies, prognostic impacts and subtype associations of various 
      amplifications and co-amplifications in breast cancers.
FAU - Letessier, Anne
AU  - Letessier A
AD  - Centre de Recherche en Cancerologie de Marseille, Departement d'Oncologie 
      Moleculaire, UMR599 Inserm/Institut Paoli-Calmettes, Marseille, France. 
      letessiera@marseille.fnclcc.fr <letessiera@marseille.fnclcc.fr>
FAU - Sircoulomb, Fabrice
AU  - Sircoulomb F
FAU - Ginestier, Christophe
AU  - Ginestier C
FAU - Cervera, Nathalie
AU  - Cervera N
FAU - Monville, Florence
AU  - Monville F
FAU - Gelsi-Boyer, Veronique
AU  - Gelsi-Boyer V
FAU - Esterni, Benjamin
AU  - Esterni B
FAU - Geneix, Jeannine
AU  - Geneix J
FAU - Finetti, Pascal
AU  - Finetti P
FAU - Zemmour, Christophe
AU  - Zemmour C
FAU - Viens, Patrice
AU  - Viens P
FAU - Charafe-Jauffret, Emmanuelle
AU  - Charafe-Jauffret E
FAU - Jacquemier, Jocelyne
AU  - Jacquemier J
FAU - Birnbaum, Daniel
AU  - Birnbaum D
FAU - Chaffanet, Max
AU  - Chaffanet M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061013
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers
MH  - Breast Neoplasms/*genetics
MH  - Carcinoma/*genetics
MH  - *Chromosomes, Human, Pair 11
MH  - *Chromosomes, Human, Pair 12
MH  - *Chromosomes, Human, Pair 17
MH  - *Chromosomes, Human, Pair 20
MH  - *Chromosomes, Human, Pair 8
MH  - Female
MH  - *Gene Amplification
MH  - Gene Frequency
MH  - Humans
MH  - Middle Aged
MH  - Models, Biological
MH  - Neoplasm Metastasis/diagnosis
MH  - Prognosis
MH  - Statistics as Topic
PMC - PMC1626089
EDAT- 2006/10/17 09:00
MHDA- 2006/12/09 09:00
PMCR- 2006/10/13
CRDT- 2006/10/17 09:00
PHST- 2006/08/18 00:00 [received]
PHST- 2006/10/13 00:00 [accepted]
PHST- 2006/10/17 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/10/17 09:00 [entrez]
PHST- 2006/10/13 00:00 [pmc-release]
AID - 1471-2407-6-245 [pii]
AID - 10.1186/1471-2407-6-245 [doi]
PST - epublish
SO  - BMC Cancer. 2006 Oct 13;6:245. doi: 10.1186/1471-2407-6-245.